Takeda Pharmaceutical Company Limited

Scohia Pharma, Inc.

Yuko Hitomi

Yasufumi Miyamoto

Yasuhiro Hirata

Seiji Miwatashi

Tomohiro Okawa

Koji Watanabe

Nobuyuki Takakura

Hideki Furukawa

Akito Shibuya

Jumpei Aida

Naoyoshi Noguchi

Takeshi Yamasaki

Hideo Suzuki

Tsuyoshi Maekawa

Shizuo Kasai

Toshitake Kobayashi

Yayoi Nakayama

Satoshi Sasaki

Norihito Tokunaga

Kazuaki Takami

Shigemitsu Matsumoto

Yayoi Yoshitomi

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

Aromatic compound

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy. 

Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

Aromatic compounds with GPR40 agonistic activity

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Aromatic ring compound

Growing community of inventors

Kanagawa, Japan

Yuko Hitomi